Synthesis of GMP grade Apilimod for COVID 19 Clinical Trials
- Funded by University of Minnesota
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Funder
University of MinnesotaPrincipal Investigator
PhD. Ricardo BattaglinoResearch Location
United States of AmericaLead Research Institution
Medical School, University of MinnesotaResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
N/A
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Led by Ricardo Battaglino, PhD, professor and vice chair of research, Department of Rehabilitation Medicine, this study's goal is to generate Good Manufacturing Practices grade Apilimod (Minnemod) for future clinical trials. Other team members are Leslie Morse, DO, head of the Department of Rehabilitation Medicine, and Vadim Gurvich, PhD, director of ITDD Chemical Process and Development Core. Apilimod has been tested as an anti-cancer drug and has been shown to have possible applications in the treatment of viral infections, including Ebola virus. "We expect Apilimod to be 100-times more potent than other inhibitors such as hydroxychloroquine and chloroquine that have been tested for COVID-19 treatments," said Battaglino.